Traws Pharma, Inc. (TRAW)
TRAW Stock Price Chart
Explore Traws Pharma, Inc. interactive price chart. Choose custom timeframes to analyze TRAW price movements and trends.
TRAW Company Profile
Discover essential business fundamentals and corporate details for Traws Pharma, Inc. (TRAW) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
—
Employees
6.00
Website
https://www.trawspharma.comCEO
Iain D. Dukes DPHIL,
Description
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
TRAW Financial Timeline
Browse a chronological timeline of Traws Pharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 12 Nov 2025
Earnings released on 14 Aug 2025
EPS came in at -$0.11 surpassing the estimated -$8.75 by +98.74%, while revenue for the quarter reached $2.73M , beating expectations by +4.46K%.
Earnings released on 15 May 2025
EPS came in at $2.09 surpassing the estimated -$8.04 by +126.00%, while revenue for the quarter reached $57.00K , missing expectations by -5.00%.
Earnings released on 31 Mar 2025
EPS came in at $95.66 surpassing the estimated -$9.55 by +1.10K%, while revenue for the quarter reached $56.00K , missing expectations by -6.67%.
Earnings released on 14 Nov 2024
EPS came in at -$8.81 falling short of the estimated -$6.25 by -40.96%, while revenue for the quarter reached $57.00K , missing expectations by -5.00%.
Stock split effective on 23 Sept 2024
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 Aug 2024
EPS came in at -$121.75 falling short of the estimated -$6.25 by -1.85K%, while revenue for the quarter reached $57.00K , missing expectations by -5.00%.
Earnings released on 15 May 2024
EPS came in at -$6.00 matching the estimated -$6.00, while revenue for the quarter reached $56.00K , missing expectations by -6.67%.
Earnings released on 14 Mar 2024
EPS came in at -$0.19 surpassing the estimated -$0.25 by +24.00%, while revenue for the quarter reached $56.00K .
Earnings released on 14 Nov 2023
EPS came in at -$0.23 surpassing the estimated -$0.26 by +11.54%, while revenue for the quarter reached $57.00K , missing expectations by -17.69%.
Earnings released on 30 Jun 2023
EPS came in at -$0.20 surpassing the estimated -$7.81 by +97.41%, while revenue for the quarter reached $57.00K , missing expectations by -17.69%.
Earnings released on 31 Mar 2023
EPS came in at -$0.28 surpassing the estimated -$7.44 by +96.30%, while revenue for the quarter reached $56.00K , missing expectations by -29.11%.
Earnings released on 30 Dec 2022
EPS came in at -$0.26 surpassing the estimated -$6.94 by +96.27%, while revenue for the quarter reached $56.00K , missing expectations by -30.00%.
Earnings released on 29 Sept 2022
EPS came in at -$0.26 surpassing the estimated -$5.31 by +95.14%, while revenue for the quarter reached $57.00K , missing expectations by -22.62%.
Earnings released on 29 Jun 2022
EPS came in at -$0.19 surpassing the estimated -$0.20 by +2.53%, while revenue for the quarter reached $57.00K , missing expectations by -21.92%.
Earnings released on 30 Mar 2022
EPS came in at -$0.20 , while revenue for the quarter reached $56.00K .
Earnings released on 30 Dec 2021
EPS came in at -$0.18 surpassing the estimated -$0.19 by +3.93%, while revenue for the quarter reached $56.00K , missing expectations by -29.11%.
Earnings released on 29 Sept 2021
EPS came in at -$0.22 , while revenue for the quarter reached $57.00K .
Earnings released on 29 Jun 2021
EPS came in at -$0.27 , while revenue for the quarter reached $57.00K .
Stock split effective on 21 May 2021
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Mar 2021
EPS came in at -$0.32 , while revenue for the quarter reached $56.00K .
Earnings released on 31 Dec 2020
EPS came in at -$0.54 , while revenue for the quarter reached $231.00K .
Earnings released on 30 Sept 2020
EPS came in at -$0.52 , while revenue for the quarter reached $66.00K .
TRAW Stock Performance
Access detailed TRAW performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.